Comparative evaluation of purine dysmetabolism in gastric and pulmonary adenocarcinomas

Authors

  • Y.V. Dumanskiy R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • O.Y. Stoliarova National Cancer Institute
  • О.V. Syniachenko Donetsk National Medical University, Lyman 84404, Ukraine
  • R.F. Aliev Donetsk National Medical University, Lyman 84404, Ukraine
  • М.V. Iermolaeva Donetsk National Medical University, Lyman 84404, Ukraine
  • О.P. Sokrut Donetsk National Medical University, Lyman 84404, Ukraine

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-3.15068

Keywords:

adenocarcinoma, cancer, lung, metabolism, purines, stomach

Abstract

Summary. Aim: To study the state of purine metabolism in gastric (GAC) and pulmonary (PAC) adenocarcinomas and to assess its clinical and pathogenetic significance. Patients and Methods: One hundred and six male patients were examined, among whom were 63 subjects aged 34 to 79 suffering from GAC, and 43 subjects aged 24 to 76 suffering from PAC. In GAC, the ratio of the pyloric, corporeal and antral localization of the tumor and variant of overall gastric lesion accounted to 24:5:1:1; and that of the central and peripheral PAC was 2:1. Serum levels of purine metabolism products (uric acid, oxypurinol, adenine, guanine, xanthine, hypoxanthine) were measured and activities of xanthine oxidase, xanthine deaminase, adenosine deaminase and 5-nucleotidase were analyzed. Results: Purine metabolism disorders are observed in all GAC and 91% of PAC patients; among other things, hyperuricemia is observed in ¾ and ½ of cases, respectively; moreover, the nature of changes is more pronounced in gastric cancer and, in both groups of patients, these indices reflect the disease course severity, are associated with the neoplastic process localization, have a predictive value, trigger the development of metastases. Conclusion: Сhanges in purine metabolism are involved in the pathogenetic patterns of GAC and PAC, reflect the course of the tumor process, are associated with tumor localization and have prognostic significance.

References

Hou C, Liu D, Wang M, et al. Novel xanthine oxidase-based cell model using HK-2 cell for screening antihyperuricemic functional compounds. Free Radic Biol Med 2019 20: 135–45.

Bjorge T, Lukanova A, Jonsson H, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomark Prev 2010; 19: 1737–45.

Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders — facts and controversies. Biochem Med 2012; 22: 63–75.

Kim HJ, Kim JE, Jung JH, et al. Uric acid is a risk indicator for metabolic syndrome-related colorectal adenoma: results in a Korean population receiving screening colonoscopy. Korean J Gastroenterol 2015; 66: 202–8.

Yue CF, Feng PN, Yao ZR, et al. High serum uric acid concentration predicts poor survival in patients with breast cancer. Clin Chim Acta 2017; 473: 160–5.

Tu H, Wen CP, Tsai SP, et al. Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ 2018; 31: 134.

Baey C, Yang J, Ronchese F, Harper JL. Hyperuricaemic UrahPlt2/Plt2 mice show altered T cell proliferation and defective tumor immunity after local immunotherapy with Poly I:C. PLoS One 2018; 13: 0206827.

Kaji K, Hashiba A, Uotani C, et al. Grading of atrophic gastritis is useful for risk stratification in endoscopic screening for gastric cancer. Am J Gastroenterol 2019; 114: 71–9.

Yiu A, Van Hemelrijck M, Garmo H, et al. Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study. Oncotarget 2017; 26: 42332–42.

Dovell F, Boffetta P. Serum uric acid and cancer mortality and incidence: a systematic review and meta-analysis. Eur J Cancer Prev 2018; 27: 399–405.

Garcia-Gil M, Camici M, Allegrini S, et al. Emerging role of purine metabolizing enzymes in brain function and tumors. Int J Mol Sci 2018; 19: 3598.

Sun Q, Zhao W, Wang L, et al. Integration of metabolomic and transcriptomic profiles to identify biomarkers in serum of lung cancer. J Cell Biochem 2019; 25: 28482.

Hande KR, Noone SM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1994; 76: 47–51.

Oreshnikov YV, Oreshnikova SF. Purines of blood and liquids in pregnant. Anesteziol Reanimatol 2015; 60: 29–33 (in Russian).

Ipata PL, Tozzi MG. Recent advances in structure and function of cytosolic IMP-GMP specific 5′-nucleotidase II (cN-II). Purinergic Signal 2016; 2: 669–75.

Bricard G, Cadassou O, Cassagnes LE, et al. The cytosolic 5′-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells. Oncotarget 2017; 8: 67380–93.

Pesi R, Petrotto E, Colombaioni L, et al. Cytosolic 5′-nucleotidase ii silencing in a human lung carcinoma cell line opposes cancer phenotype with a concomitant increase in p53 phosphorylation. Int J Mol Sci 2018; 19: 2115.

Battelli MG, Bortolotti M, Polito L, Bolognesi A. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase. Redox Biol 2019; 21: 101070.

Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med 2012; 1: 1–16.

Downloads

Published

31.05.2023

How to Cite

Dumanskiy, Y., Stoliarova, O., Syniachenko О., Aliev, R., Iermolaeva М., & Sokrut О. (2023). Comparative evaluation of purine dysmetabolism in gastric and pulmonary adenocarcinomas. Experimental Oncology, 42(3), 220–223. https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-3.15068

Issue

Section

Original contributions